#United States #San Diego #Oncolytics Biotech #pelareorep #Annual General Meeting

Oncolytics Biotech® Announces AGM Voting Results

Oncolytics Biotech® Inc. (symbol: ONCY on Nasdaq, ONC on TSX) is a noteworthy player in the clinical-stage immunotherapy landscape, primarily recognized for developing pelareorep, an innovative immunotherapeutic agent. The Corporation recently disclosed the results from its Annual General Meeting (AGM) of Shareholders, which took place on August 8, 2025, an event that saw a total participation of 37.42% of the outstanding shares, represented either in person or by proxy.

During the AGM, shareholders voted on a slate of eight director nominees proposed by the company, resulting in their collective election. This means these individuals will serve in their roles until the next scheduled AGM or until their successors are appointed or elected. Below are the results for each nominee:

• - Patricia Andrews: 10,498,328 votes (88.83% in favor, 11.17% withheld)
• - Deborah M. Brown: 10,115,110 votes (85.58% in favor, 14.42% withheld)
• - Jared Kelly: 10,830,605 votes (91.64% in favor, 8.36% withheld)
• - Angela Holtham: 10,175,887 votes (86.10% in favor, 13.90% withheld)
• - James T. Parsons: 10,172,958 votes (86.07% in favor, 13.93% withheld)
• - Wayne Pisano: 10,148,894 votes (85.87% in favor, 14.13% withheld)
• - Jonathan Rigby: 9,508,770 votes (80.45% in favor, 19.55% withheld)
• - Bernd R. Seizinger: 10,269,441 votes (86.89% in favor, 13.11% withheld)

In addition to the election of the director nominees, shareholders considered and approved several other resolutions. These included fixing the number of directors at eight for the upcoming year and the reappointment of auditors for the Corporation for the same period.

For more details on the agenda and outcomes of the meeting, interested parties can refer to the management information circular available on the SEDAR platform at SEDAR. The comprehensive voting results for all matters discussed during the AGM will be formally filed on SEDAR.

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc. is making strides in the biotech sector through its development of pelareorep. This agent is delivered intravenously and has exhibited encouraging preliminary results in studies targeting various cancers. Notably, it has shown promise in first-line pancreatic cancer treatments as well as in randomized Phase 2 studies for metastatic breast cancer. Early-phase investigations in anal and colorectal cancers indicate that pelareorep can effectively convert traditionally 'cold' tumors into 'hot' tumors, thus harnessing the body's anti-cancer immune responses.

The company is advancing clinical trials that combine pelareorep with chemotherapy or checkpoint inhibitors specifically aimed at metastatic pancreatic and breast cancers, both of which currently hold Fast Track designation from the FDA. Furthermore, Oncolytics is actively pursuing strategic partnerships to enhance development efforts and maximize its commercial potential. To discover more about Oncolytics Biotech and its innovative therapies, please visit their official site at Oncolytics Biotech or follow them on social media platforms like LinkedIn and X (@oncolytics).